IL149147A0 - Use of oxcarbazepine for the manufacture of oral dosage form medicament - Google Patents

Use of oxcarbazepine for the manufacture of oral dosage form medicament

Info

Publication number
IL149147A0
IL149147A0 IL14914700A IL14914700A IL149147A0 IL 149147 A0 IL149147 A0 IL 149147A0 IL 14914700 A IL14914700 A IL 14914700A IL 14914700 A IL14914700 A IL 14914700A IL 149147 A0 IL149147 A0 IL 149147A0
Authority
IL
Israel
Prior art keywords
oxcarbazepine
oral dosage
manufacture
dosage form
form medicament
Prior art date
Application number
IL14914700A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL149147A0 publication Critical patent/IL149147A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL14914700A 1999-11-02 2000-10-31 Use of oxcarbazepine for the manufacture of oral dosage form medicament IL149147A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9925962.4A GB9925962D0 (en) 1999-11-02 1999-11-02 Organic compounds
PCT/EP2000/010764 WO2001032183A2 (en) 1999-11-02 2000-10-31 Pharmaceutical compositions comprising oxcarbazepine

Publications (1)

Publication Number Publication Date
IL149147A0 true IL149147A0 (en) 2003-01-12

Family

ID=10863836

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14914700A IL149147A0 (en) 1999-11-02 2000-10-31 Use of oxcarbazepine for the manufacture of oral dosage form medicament
IL149147A IL149147A (en) 1999-11-02 2002-04-15 Use of oxcarbazepine in the manufacture of drugs for the treatment of seizures
IL205504A IL205504A0 (en) 1999-11-02 2010-05-03 Pharmaceutical compositions

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL149147A IL149147A (en) 1999-11-02 2002-04-15 Use of oxcarbazepine in the manufacture of drugs for the treatment of seizures
IL205504A IL205504A0 (en) 1999-11-02 2010-05-03 Pharmaceutical compositions

Country Status (25)

Country Link
US (3) US20060079502A1 (de)
EP (1) EP1242091B1 (de)
JP (3) JP2003514780A (de)
KR (1) KR100493836B1 (de)
CN (1) CN1407894A (de)
AT (1) ATE401892T1 (de)
AU (1) AU777705B2 (de)
BR (1) BR0015188A (de)
CA (1) CA2388609C (de)
CZ (1) CZ302847B6 (de)
DE (1) DE60039629D1 (de)
ES (1) ES2311001T3 (de)
GB (1) GB9925962D0 (de)
HK (1) HK1050839B (de)
HU (1) HU227685B1 (de)
IL (3) IL149147A0 (de)
MX (1) MXPA02004389A (de)
NO (1) NO330947B1 (de)
NZ (1) NZ518378A (de)
PL (1) PL200273B1 (de)
RU (1) RU2330666C2 (de)
SK (1) SK287479B6 (de)
TR (1) TR200200951T2 (de)
WO (1) WO2001032183A2 (de)
ZA (1) ZA200203394B (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
AU2003240654A1 (en) * 2002-05-31 2003-12-19 Desitin Arzneimittel Gmbh Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
EP1528927A1 (de) * 2002-08-06 2005-05-11 Novartis AG Verwendung von carboxamiden für die behandlung von tinnitus
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
DE602004023861D1 (de) * 2003-09-03 2009-12-10 Novartis Ag Verwendung von oxcarbazepin zur verbesserung des schlafes bei patienten die an chronischem schmerz leiden
PE20060124A1 (es) * 2004-03-22 2006-03-07 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
CA2559239C (en) * 2004-04-13 2021-04-06 Boehringer Ingelheim International Gmbh Use of simethicone and sodium picosulphate in constipated patients suffering from bloated feeling and gas discomfort during the night
US20090196919A1 (en) * 2004-10-25 2009-08-06 Ajay Singla Oxcarbazepine dosage forms
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007008576A2 (en) * 2005-07-08 2007-01-18 Taro Pharmaceuticals U.S.A., Inc. Oxcarbazepine formulation
WO2007029093A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Pharmaceutical dosage forms of oxcarbazepine
WO2007089247A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
EP2029118A2 (de) * 2006-01-31 2009-03-04 Teva Pharmaceutical Industries, Inc. Pharmazeutische formulierung von oxcarbazepin und ihr herstellungsverfahren, wobei oxcarbazepin eine breite und multimodale teilchengrössenverteilung aufweist
EP2359830B1 (de) 2006-04-26 2012-09-19 Supernus Pharmaceuticals, Inc. Oxcarbazepinpräparate für kontrollierte Freisetzung mit sigmoidalem Freisetzungsprofil
US20080138403A1 (en) * 2006-12-08 2008-06-12 Sun Pharmaceutical Industries Ltd. Pharmaceutical dosage forms of oxcarbazepine
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
CA2681628C (en) 2007-03-16 2016-10-18 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
KR20100105802A (ko) * 2007-04-19 2010-09-29 콘서트 파마슈티컬즈, 인크. 중수소화된 모르폴리닐 화합물
ES2401914T3 (es) 2007-04-25 2013-04-25 Concert Pharmaceuticals Inc. Análogos de Cilostazol
MX385316B (es) 2007-05-01 2025-03-18 Concert Pharmaceuticals Inc Compuestos de morfinano.
WO2008137461A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
EP4183787A1 (de) 2007-05-01 2023-05-24 Concert Pharmaceuticals Inc. Morphinanverbindungen
AU2008247818B2 (en) 2007-05-01 2011-10-20 Sun Pharmaceutical Industries, Inc. Morphinan compounds
KR20120029480A (ko) 2007-06-12 2012-03-26 콘서트 파마슈티컬즈, 인크. 아자펩티드 유도체
EP2212298B1 (de) * 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuteriertes etravirin
KR20100121527A (ko) 2008-02-29 2010-11-17 콘서트 파마슈티컬즈, 인크. 치환된 잔틴 유도체
US20110160253A1 (en) * 2008-05-28 2011-06-30 Harbeson Scott L Deuterated tizanidine
US20100221221A1 (en) * 2008-08-12 2010-09-02 Concert Pharmaceuticals Inc. N-phenyl-2-pyrimidineamine derivatives
MX361542B (es) 2008-09-19 2018-12-10 Concert Pharmaceuticals Inc Compuestos de morfinan.
US20120083487A1 (en) 2008-10-30 2012-04-05 Amanda Thomas Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurolgical diseases, intractable and chronic pain and brain injury
US20120053169A1 (en) 2008-10-30 2012-03-01 Amanda Thomas Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
US9096646B2 (en) 2008-11-04 2015-08-04 Anchor Therapeutics, Inc. CXCR4 receptor compounds
WO2010065755A1 (en) 2008-12-04 2010-06-10 Concert Pharmaceuticals, Inc. Deuterated pyridinones
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
BRPI1009199A2 (pt) 2009-03-17 2016-03-08 Concert Pharmaceuticals Inc compostos de pirazinoisoquinolina
US20120244122A1 (en) 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
US8501738B2 (en) 2009-06-23 2013-08-06 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
WO2011047315A1 (en) 2009-10-15 2011-04-21 Concert Pharmaceuticals, Inc. Subsitituted benzimidazoles
US20110098265A1 (en) * 2009-10-28 2011-04-28 Neuroscience, Inc. Methods for reducing cravings and impulses associated with addictive and compulsive behaviors
WO2011060216A1 (en) 2009-11-12 2011-05-19 Concert Pharmaceuticals Inc. Substituted azaindoles
US20140018379A1 (en) 2010-02-18 2014-01-16 Concert Pharmaceuticals Inc. Pyrimidine derivatives
WO2011106703A2 (en) 2010-02-26 2011-09-01 Anchor Therapeutics, Inc. Cxcr4 receptor compounds
US8513434B2 (en) 2010-03-02 2013-08-20 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
EP2616467A1 (de) 2010-09-13 2013-07-24 Concert Pharmaceuticals Inc. Substituierte azaindole
WO2012065028A2 (en) 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
US8447329B2 (en) 2011-02-08 2013-05-21 Longsand Limited Method for spatially-accurate location of a device using audio-visual information
EP2678337A1 (de) 2011-02-25 2014-01-01 Concert Pharmaceuticals Inc. 2-amino-naphthyridin-derivate
WO2012129381A1 (en) 2011-03-22 2012-09-27 Concert Pharmaceuticals Inc. Deuterated preladenant
WO2012151361A1 (en) 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2012154728A1 (en) 2011-05-10 2012-11-15 Concert Pharmaceuticals Inc. Deuterated n-butyl bumetanide
DK3235812T3 (da) 2011-05-18 2019-11-25 Vertex Pharmaceuticals Europe Ltd Deutererede derivater af ivacaftor
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
EP2802596A1 (de) 2012-01-09 2014-11-19 Anchor Therapeutics, Inc. Apj-rezeptorverbindungen
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
KR20150002779A (ko) 2012-04-13 2015-01-07 콘서트 파마슈티컬즈, 인크. 치환된 크산틴 유도체
US9249093B2 (en) 2012-04-20 2016-02-02 Concert Pharmaceuticals, Inc. Deuterated rigosertib
DK3882249T3 (da) 2012-06-15 2025-08-25 Sun Pharmaceutical Ind Inc Deutererede derivater af ruxolitinib
EP2885267B1 (de) 2012-07-12 2018-09-05 Concert Pharmaceuticals, Inc. Deuteriertes idebenon
EP3492472A1 (de) 2012-08-17 2019-06-05 Concert Pharmaceuticals Inc. Deuteriertes baricitinib mit verbesserter metabolischer stabilität als jak1 und jak2 kinase inhibitor zur behandlung von rheumatoider arthritis
WO2014078842A1 (en) 2012-11-19 2014-05-22 Concert Pharmaceuticals, Inc. Deuterated cftr potentiators
US20150299166A1 (en) 2012-12-20 2015-10-22 Concert Pharmaceuticals, Inc. Deuterated alk inhibitors
ES2882258T3 (es) 2012-12-21 2021-12-01 Mayo Found Medical Education & Res Métodos y materiales para tratar estenosis de la válvula aórtica calcificada
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
CA2906396A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
CA2904054A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals, Inc. Deuterated palbociclib
HU231191B1 (hu) 2013-04-15 2021-08-30 Szegedi Tudományegyetem Izotóp tartalmú morfin molekulák
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
WO2015010045A1 (en) 2013-07-18 2015-01-22 Anchor Therapeutics, Inc. Apj receptor compounds
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
WO2015063670A1 (en) * 2013-10-30 2015-05-07 Wockhardt Limited Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof
EP3105232B1 (de) 2014-02-10 2019-08-28 Concert Pharmaceuticals Inc. Substituierte triazolobenzodiazepine
US20170216296A1 (en) 2014-04-18 2017-08-03 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia
WO2015179772A1 (en) 2014-05-23 2015-11-26 Concert Pharmaceuticals, Inc. Deuterated phenylquinazolinone and phenylisoquinolinone compounds
PE20170664A1 (es) 2014-06-06 2017-06-10 Res Triangle Inst Agonistas del receptor de apelina(apj) y usos de los mismos
EP4180041A1 (de) 2014-08-07 2023-05-17 Mayo Foundation for Medical Education and Research Verbindungen und verfahren zur behandlung von krebs
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
WO2016073545A1 (en) 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
WO2016089814A1 (en) 2014-12-02 2016-06-09 Concert Pharmaceuticals, Inc. Deuterated analogues of daclatasvir
WO2016105547A1 (en) 2014-12-24 2016-06-30 Concert Pharmaceuticals, Inc. Deuterated dasabuvir
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
EP3265440A1 (de) 2015-03-06 2018-01-10 Concert Pharmaceuticals Inc. Deuteriertes emricasan
HK1249893A1 (zh) 2015-03-31 2018-11-16 Vertex Pharmaceuticals (Europe) Limited 氘代vx-661
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
WO2017020005A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Morphinan compounds for use in treating agitation
WO2017020002A1 (en) 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
US20180353500A1 (en) 2015-09-21 2018-12-13 Vertex Pharmaceuticals (Europe) Limited Administration of deuterated cftr potentiators
US11267777B2 (en) 2015-11-19 2022-03-08 Concert Pharmaceuticals, Inc. Deuterated EPI-743
PE20190258A1 (es) 2015-12-09 2019-02-25 Res Triangle Inst Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos
WO2017147003A1 (en) 2016-02-26 2017-08-31 Novobiotic Pharmaceuticals, Llc Novel macrocyclic antibiotics and uses thereof
LT3452039T (lt) 2016-05-04 2024-10-25 Sun Pharmaceutical Industries, Inc. Plaukų slinkimo sutrikimo gydymas deuterintais jak inhibitoriais
CN115215801A (zh) 2016-07-04 2022-10-21 雅芳制药公司 氘代右美沙芬的合成方法
CN109789103A (zh) 2016-08-01 2019-05-21 布里格姆妇女医院 用于递送蛋白质和肽的颗粒
EP3589659B1 (de) 2017-02-28 2025-04-09 Mayo Foundation for Medical Education and Research Kombinationen zur verwendung bei der behandlung von krebs
US11278025B2 (en) 2017-05-17 2022-03-22 The General Hospital Corporation Antibiotic compounds
CA3063953A1 (en) 2017-05-19 2018-11-22 Superb Wisdom Limited Derivatives of resiquimod
AU2018371784B2 (en) 2017-11-22 2024-10-17 Sun Pharmaceutical Industries, Inc. Deuterated analogs of D-serine and uses thereof
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
MX2021012409A (es) 2019-04-10 2021-11-12 Mayo Found Medical Education & Res Metodos y materiales para el tratamiento dependiente del genero de la disfuncion cardiovascular.
EP4054545A4 (de) * 2019-11-08 2024-02-14 Lyndra Therapeutics, Inc. Magenverweilsysteme zur verabreichung von wirkstoffen
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
CA3184471A1 (en) 2020-05-27 2021-12-02 The Penn State Research Foundation Antibacterial compounds
IL302401A (en) 2020-10-28 2023-06-01 Sun Pharmaceutical Ind Inc Regimens for the treatment of hair loss disorders with faded JAC inhibitors
JP2024507574A (ja) 2021-02-25 2024-02-20 リサーチ トライアングル インスティテュート アペリン受容体アゴニストとしてのヘテロアリール誘導体
CN118159272A (zh) 2021-08-11 2024-06-07 太阳医药工业公司 用氘化的jak抑制剂来治疗脱发病症
EP4384173A1 (de) 2021-08-12 2024-06-19 Sun Pharmaceutical Industries, Inc. Behandlung von auf jak-hemmung ansprechenden erkrankungen mit prodrugs von jak-hemmern
EP4518863A1 (de) 2022-05-04 2025-03-12 Sun Pharmaceutical Industries, Inc. Dosierungsschemata zur behandlung mit deuterierten jak-hemmern

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US20020022056A1 (en) * 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones

Also Published As

Publication number Publication date
RU2002113752A (ru) 2004-01-10
PL200273B1 (pl) 2008-12-31
JP2003514780A (ja) 2003-04-22
AU777705B2 (en) 2004-10-28
EP1242091A2 (de) 2002-09-25
ATE401892T1 (de) 2008-08-15
HUP0203556A2 (hu) 2003-02-28
NO20022058L (no) 2002-06-27
TR200200951T2 (tr) 2003-01-21
MXPA02004389A (es) 2002-09-02
CZ20021529A3 (cs) 2002-08-14
ZA200203394B (en) 2003-07-29
GB9925962D0 (en) 1999-12-29
SK5842002A3 (en) 2002-08-06
HU227685B1 (en) 2011-11-28
SK287479B6 (sk) 2010-11-08
KR20020049004A (ko) 2002-06-24
HK1050839B (en) 2009-01-30
WO2001032183A2 (en) 2001-05-10
NZ518378A (en) 2004-10-29
IL149147A (en) 2010-11-30
US20070037792A1 (en) 2007-02-15
CA2388609C (en) 2011-01-04
AU1997801A (en) 2001-05-14
US20090252793A1 (en) 2009-10-08
ES2311001T3 (es) 2009-02-01
EP1242091B1 (de) 2008-07-23
BR0015188A (pt) 2002-11-05
NO20022058D0 (no) 2002-04-30
US20060079502A1 (en) 2006-04-13
JP2012211202A (ja) 2012-11-01
IL205504A0 (en) 2011-07-31
HUP0203556A3 (en) 2004-03-01
CN1407894A (zh) 2003-04-02
HK1050839A1 (en) 2003-07-11
WO2001032183A3 (en) 2002-07-04
CZ302847B6 (cs) 2011-12-14
DE60039629D1 (de) 2008-09-04
JP2007224041A (ja) 2007-09-06
KR100493836B1 (ko) 2005-06-08
RU2330666C2 (ru) 2008-08-10
CA2388609A1 (en) 2001-05-10
NO330947B1 (no) 2011-08-22
PL366314A1 (en) 2005-01-24

Similar Documents

Publication Publication Date Title
IL205504A0 (en) Pharmaceutical compositions
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
MY127290A (en) New use of flibanserin
IL205262A (en) Use of Risderdone Acid or its Pharmaceutical Salt to produce oral medication once a month for the prevention and treatment of osteoporosis
NZ595941A (en) Treatment of neurodegeneration and neuroinflammation
MXPA03007712A (es) Sales farmaceuticas.
DE69936002D1 (de) Angepasster löffel zur oralen medikamenten-verabreichung
MXPA03006476A (es) Composiciones farmaceuticas, formas de dosificacion y metodos para administracion oral de epotilonas.
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
MEP55308A (en) New pharmaceutical compositions containing flibanserin polymorph a
AU4024797A (en) Use of arachidonic acid and/or docosahexanoic acid for the manufacture of a medicament for the treatment of dyspraxia
HUP0203303A3 (en) Compositions for administering taxanes orally to human patients
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
DE602004016963D1 (en) Therapeutisches system mit amoxicillin und clavulansäure
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
SG145717A1 (en) Composition for releasing a weak base for an extended period of time
IL146032A0 (en) Use of n-acetylcysteine for the preparation of a medicament suitable for intravenous administration to prevent oxidative stress in dialysed patients
HUP0400495A3 (en) Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue
SG146631A1 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
TW200501967A (en) Nemorubicin for use in the preparation of a medicament for liver disease
PL367616A1 (en) Use of acetyl l-carnitine for the preparation of a medication for the preventive therapy for pain
AU2001295884A1 (en) Dispenser for endermic administration of drug
PL373758A1 (en) Synergistic interaction of abacavir and alovudine
PL367628A1 (en) Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia